Navigation Links
Cyclacel Pharmaceuticals to Present Preclinical Data on,Sapacitabine and Seliciclib at AACR

division cycle. Both sapacitabine and its major metabolite, CNDAC, have demonstrated in preclinical studies potent anti-tumor activity in both hematological and solid tumors. Sapacitabine has been administered to approximately 150 patients enrolled in three Phase I clinical trials in solid tumors and a Phase I study in hematological tumors conducted by Dr. Hagop Kantarjian, Professor of Medicine and Chairman of the Leukemia Department at M.D. Anderson Cancer Center (UTMDACC) in Houston, Texas. Based on the results of these studies, Cyclacel plans to initiate Phase II trials of sapacitabine in 2007 to evaluate the drug in both hematological and solid tumors.

About CYC116

CYC116 is an orally-available inhibitor of Aurora kinases A and B and VEGFR2. In December 2006, Cyclacel submitted to FDA an Investigational New Drug (IND) application to begin clinical trials of CYC116. Phase I trials will be conducted at multiple centers in the US evaluating the safety profile of CYC116 as a single agent in patients with both hematological and solid tumors.

Please visit http://www.cyclacel.com/cyc/investors/news/pressreleases/ for additional information on the above highlights.

Note: The Cyclacel logo and Cyclacel(R) are trademarks of Cyclacel Pharmaceuticals, Inc.

Risk Factors

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety, and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include the risk tha
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
2. Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study Results at the American Society of Clinical Oncology Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:7/11/2014)... 2014 Research and Markets has ... Medical X-ray Film Industry Report 2014" report to ... Global And Chinese Medical X-Ray Film Industry ... the current state of the Global medical X-ray film ... The report provides a basic overview of the industry ...
(Date:7/11/2014)... 2014 On Thursday, July ... the Dow Jones Industrial Average finished the day 0.42% lower ... 0.41%. The losses were broad based as eight out of ... Health Care Sector Index ended the day at 711.88, down ... one month. Investor-Edge has initiated coverage on the following equities: ...
(Date:7/11/2014)... , July 11, 2014 Neurelis, Inc. ... ("Biotie") to end the option held by Biotie to ... further development of NRL-1 (intranasal diazepam) for pediatric and ... Over the past year, Biotie has advanced the ... preparation for the pivotal clinical work required for NDA ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... BEIJING, June 22, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical ... ), a leading China-based advanced in-vitro diagnostic ("IVD") ... GP Medical Technologies Co., Ltd. ("GP Medical"), has ... An Healthcare Investment Ltd. ("Da An Health") to ...
... Millstone Medical Outsourcing announced today that the ... online inventory management system.  After several months of ... password-protected system used by medical device manufacturers to ... of the enhanced inventory management system include increased ...
Cached Medicine Technology:China Medical Technologies Announces Strategic Collaboration Between its Subsidiary, GP Medical, and Da An Health 2China Medical Technologies Announces Strategic Collaboration Between its Subsidiary, GP Medical, and Da An Health 3Millstone Medical Outsourcing Introduces Advanced Version of Online Inventory Management System 2
(Date:7/14/2014)... News) -- Being physically active in middle age appears ... other types of dementia, suggest the findings from two ... physical exercise at various levels, especially in midlife, is ... Mayo Clinic, said in an Alzheimer,s Association news release. ... yet conclusive. More research is needed to determine the ...
(Date:7/14/2014)... Skin M.D. by ... on Monday, July 14th, located at 45 East ... last all week through Saturday, July 19th, with ... welcomed to attend. The business is owned by ... anti-aging, weight loss services, and sells high-end industry ...
(Date:7/14/2014)... The NIH is giving $8 million ... fund a clinical trial on light-based therapy in mesothelioma ... newly-posted article on the research. , Scientists at ... to enroll 102 pleural mesothelioma study participants ... photosensitizing drug prior to surgery. Then half will have ...
(Date:7/14/2014)... “You've probably heard the expression, 'You ... mean?” This question was posed in an article by ... Medical Group’s blog regarding how people should select what ... . , According to the article, individuals who consume ... a high risk of dehydration and consequent negative health ...
(Date:7/14/2014)... Cabin Chiang Mai, Asia’s leading inpatient addiction treatment centre, ... – a free comprehensive aftercare service for clients who ... they live in the world. , The Cabin firmly ... maintain their recovery after successfully completing primary treatment should ... As a chronic disease, addicts in recovery are always ...
Breaking Medicine News(10 mins):Health News:Staying Active May Help Prevent Dementia 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 3Health News:New Research Could Expand Availability of Light-Based Mesothelioma Therapy, According to Surviving Mesothelioma 2Health News:Drink With Your Mental Health in Mind, Advises an Article by Mental Health America Featured by Western Washington Medical Group 2Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 2Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 3
... to prevent heart failure, stroke , WEDNESDAY, Nov. ... status as the best first-line treatment in older ... research concludes. , The thiazide-type diuretic chlorthalidone outshone ... an ACE inhibitor and an alpha-receptor blocker -- ...
... to Release Statewide Data , HARRISBURG, Pa., Nov. 18 Pennsylvania ... children and adults living with autism, according to the Pennsylvania Autism ... , "With the release of this report, Pennsylvania becomes the ... prepare to meet the needs of the rapidly growing population of ...
... , CLEVELAND, Nov. 18 Hospice workers have seen patients ... them. Researchers from the Frances Payne Bolton School of Nursing ... Reserve University will study what drives the dying to resolve ... Mary Jo Prince-Paul from nursing and Julie Exline from arts ...
... captures insects, an innovative new device with nano-sized features developed ... in the blood that have broken off from a tumor. ... tumor cells, or CTCs, can provide critical information for examining ... effectiveness of therapies. Metastasis ...
... common surgical painkillers help cancer cells thrive , WEDNESDAY, ... to growing evidence that morphine and other opiate-based painkillers ... , The papers, scheduled to be presented Wednesday at ... preventing opiates from reaching lung cancer cells reduces cancer ...
... ... Organization is asking for nominations for the 2010 Innovations in Healthcare(SM) ABBY ... Event, on April 28, 2010, in Newport Beach, California. At this event, ... of the toughest problems facing healthcare today, and three will take home ...
Cached Medicine News:Health News:Diuretics Still Best Treatment for High Blood Pressure 2Health News:PA Governor Rendell: New Report Shows Demand for Autism Services will Continue to Rise 2Health News:Research Collaboration Focuses on Unfinished Business at the End of Life 2Health News:UCLA researchers create 'fly paper' to capture circulating cancer cells 2Health News:UCLA researchers create 'fly paper' to capture circulating cancer cells 3Health News:Morphine May Help Tumors Spread in Cancer Patients 2Health News:Nominate Your Favorite Innovative Healthcare Company for the 2010 ABBY Awards 2Health News:Nominate Your Favorite Innovative Healthcare Company for the 2010 ABBY Awards 3Health News:Nominate Your Favorite Innovative Healthcare Company for the 2010 ABBY Awards 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: